Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Athenex Forms $145 Million Immunoncology JV with Xiangxue and Raises $100 Million

publication date: Jul 3, 2018

Athenex, a US-China biopharma, announced two deals for China-developed drug candidates: it formed a $145 million JV with Xiangxue Life Sciences to develop T-cell receptor-engineered T cell (TCR-T) molecules for cancer. and it acquired global rights to a pegylated genetically modified human arginase from Avalon PolyTom of Hong Kong. In addition, Athenex announced a $100 million investment from Perceptive Advisors of the US to develop new drugs. The company is headquartered in Rochester, New York, with additional R&D and manufacturing facilities in Chongqing. More details....

Stock Symbol: (NSDQ: ATNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.